分享好友 资讯首页 频道列表

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

2026-02-13 09:4013350

Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra across nine diverse patient profiles and journeys, over two years1
Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin2-6
The campaign captures the patients’ clinical and emotional experiences – including before & after treatment imagery – highlighting Sculptra’s adaptability and reinforcing its role in tailored, science-backed regenerative aesthetic care1

ZUG, Switzerland -- (BUSINESS WIRE) --

Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211375008/en/

Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.2-6 With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.2,3,7-14

 

“What excites me about this unique program is how it aims to capture the nuance of clinical practice: different protocols, different goals, and different outcomes, all unified by a science-first approach to aesthetic personalization. And beyond the science, we also notice an emotional journey – seeing patients regain confidence, feel more like themselves, and experience a deeper sense of wellbeing as their natural beauty is restored over time."

 

MS. PRIYANKA CHADHA, FRCS (PLAST)
CONSULTANT PLASTIC SURGEON, GLOBAL EDUCATOR

AMER CLINIC, LONDON

 

Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients – who were all new to injectable aesthetics – over two years, offering a long-term view of how Sculptra performs over time.1 Its launch captures the patients’ personal reflections, results, and before & after treatment imagery, offering a powerful lens into both clinical outcomes and emotional impact.1

The campaign highlights the rich diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.1 Grounded in Galderma’s AART™ (Assessment, Anatomy, Range, and Treatment) methodologies and HIT™ (Holistic Individualised Treatment) protocols, it demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.1

Whether renewing natural volume, improving skin quality, or repositioning tissue for a lifted appearance, each case will highlight Sculptra’s adaptability across diverse indications and patient needs.1 As well its natural, long-lasting clinical outcomes, the campaign captures the emotional resonance of treatment, with improved confidence, self-recognition, and wellbeing seen throughout the group, while also leaving them with a positive first impression of aesthetic treatments.1

 

“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life. This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.”

 

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE CENTER FOR INNOVATION

 

Learn more about We Are All Sculptra here.

About Sculptra

Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide progressive and sustained regenerative effect across all three skin layers.2-6 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.2,15-18 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.8-11 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.2,17,19,20

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. We Are All Sculptra. 2025

1.

 

2.

 

U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed December 2025.

3.

 

Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042.

4.

 

Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France.

5.

 

Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.

6.

 

Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417.

7.

 

Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France.

8.

 

Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States.

9.

 

Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States.

10.

 

Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229.

11.

 

Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.

12.

 

Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010;62(3):448–62. doi: 10.1016/j.jaad.2009.07.040.

13.

 

Galderma. Data on File (MA-47133).

14.

 

Mu X, et al. 12-Month Effectiveness and Safety of PLLA Treatment of Midface in Chinese Subjects: A Multicenter, Randomized, No-Treatment Controlled Study. Presented at AMWC. March 30 to April 1, 2023. Monte-Carlo, Monaco.

15.

 

Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755.

16.

 

Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x.

17.

 

Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–922. doi: 10.1111/dsu.12164.

18.

 

Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239.

19.

 

Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015.

20.

 

Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC. March 30 - April 1, 2023. Monte-Carlo, Monaco.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260211375008/en/

CONTACT:

For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com

 

反对 0
举报 0
收藏 0
打赏 0
评论 0
Echodyne被指定为Trust Automation价值4.9亿美元美国空军反无人机系统工程合同的雷达系统供应商
EchoShield雷达集成至小型无人机防空系统(SUADS),助力履行4.9亿美元空军不定期交付/不确定数量(IDIQ)合同 华盛顿州柯克兰--(美国商业资讯)--雷达平台公司Echodyne今日宣布,其产品被选为Trust Automation小型无人机防空系统(SUADS)反无人机系统平台的主力雷达系统,该系统将依据2025年8月公布的4.9亿美元IDIQ合同交付给美国空军。 可快速部署型小型无人机防空系统(RD-SUADS)、固定站点型小型无人机防空系统(FS-SUADS)和远征型...

0评论2026-04-222035

迪拜本土独角兽企业领导人盛赞迪拜是塑造未来科技、推动数字经济发展的全球创新中心
阿联酋迪拜--(美国商业资讯)--多家总部位于迪拜的独角兽企业的领导人重申,迪拜酋长国是全球数字创新和科技驱动型增长的中心。这些高管强调,迪拜具有前瞻性的监管环境、先进的基础设施和吸引国际人才的能力,这些也是其对高增长数字企业的吸引力持续提升的关键因素。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260420479234/zh-CN/ 他们指出,迪拜已成长为雄心勃勃的企业的战略跳板,其灵活的商业环境支持...

0评论2026-04-221110

Horse Powertrain推出X-Range C15直驱动力总成,助力纯电车平台的混动化改造
北京--(美国商业资讯)--全球领先的创新低排放动力总成系统制造商Horse Powertrain将在2026年北京车展上发布全新“一体化”动力总成:X-Range C15直驱系统。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260419829454/zh-CN/ 这款超紧凑型X-Range C15直驱系统将全混合动力总成集成于一个共用壳体的紧凑单元中,设计安装于后副车架,通过双...

0评论2026-04-221843

有關向MIZUHO FINANCIAL GROUP, INC.( 東京: 8411)及ORIENT CORPORATION( 東京: 8585)提出股東提案,以及啟動活動網站之事宜
東京--(美國商業資訊)-- Strategic Capital, Inc.: 敬啟者: Strategic Capital, Inc.(下稱「Strategic Capital」)與INTERTRUST TRUSTEES (CAYMAN) LIMITED(僅以JAPAN-UP受託人身分行事,下稱「該基金」)簽署全權委託投資合約。該基金與Strategic Capital(下稱「我們」)在過去六個月或更長時間內,持續持有Mizuho Financial Group, Inc.(下稱「...

0评论2026-04-221170

清洁设计:SaniSure推出PETG PharmaTainer超洁净试剂瓶和发酵瓶
行业应用最广泛的PETG材料达到行业领先的洁净度、合规性和无RNase/DNase验证标准,现已覆盖完整生物工艺工作流程。 加州卡马里奥--(美国商业资讯)-- SaniSure®今日宣布推出PETG PharmaTainer™全新系列生物工艺用试剂瓶和发酵瓶,这些产品将广受认可的医用级Eastman Eastar® PETG 6763树脂(DMF备案号:9987)与SaniSure的专有工艺和先进自动化技术相结合。本次发布拓展了SaniSure成熟的PharmaT...

0评论2026-04-221687

Inspirit Capital将收购Kaplan Languages Group
伦敦--(美国商业资讯)--专注于企业分拆业务投资的Inspirit Capital欣然宣布,计划从Kaplan手中收购全球领先的语言教育平台KLG Kaplan Languages Group (“KLG”)。本次出售的所有条件均已达成,预计交易将于5月1日完成。 KLG旗下拥有Kaplan International Languages、Alpadia Language Schools、Azurlingua和ESL Education。自2006年以来,KLG...

0评论2026-04-221640

Wolters Kluwer Future Ready CFO report shows APAC CFOs embrace AI with a governancefirst mindset, closely aligned with global peers
Finance leaders across AsiaPacific recognize AI as a major force reshaping finance, while advancing adoption with disciplined focus on governance, value, and oversight SINGAPORE--(BUSINESS WIRE)--CFOs across AsiaPacific are accelerating ...

0评论2026-04-221597

Chemelex对Algo8进行少数股权投资,以推动AI驱动的制造业发展
休斯顿--(美国商业资讯)--电热和传感解决方案领域的全球领导者Chemelex今日宣布,已对工业人工智能(AI)公司Algo8进行少数股权投资,以加速AI在制造业中的应用。 本次投资将支持Algo8进一步开展技术研发,同时使Chemelex能够强化其制造流程、提升生产效率,并持续向客户交付高品质产品。 Chemelex首席执行官David Prystash将加入Algo8的顾问委员会。 此次合作建立在现有商业合作基础之上,也体现了Chemelex致力于运用先进技术,提升其全球制...

0评论2026-04-221416

轻松入夏* *叠穿随心 一眼盟可睐
由Jamie Dornan出镜演绎的全球广告大片,主题“轻松入夏”(Puffy Summer)所呈现的不只是季节的更替,它代表着盟可睐Moncler品牌基因在更轻盈、更明亮的户外时光中的延伸与进化。 米兰--(美国商业资讯)--进入悠闲松弛的夏日季,Moncler Collection 为更轻盈、更明媚的户外时光重新构想品牌标志性的蓬松质感。全新概念体现在一系列应对换季天气的服饰中:质感柔和、廓形立体、色彩缤纷,恰到好处的蓬松感塑就叠穿风格——由Jamie Dornan...

0评论2026-04-221941

Perma-Pipe International Holdings, Inc.公布创纪录的2025财年第四季度及全年业绩:净销售额增长33%,净利润增长89%
本季度净销售额增至5,510万美元,全年达2.109亿美元,上年同期分别为4,500万美元和1.584亿美元 本季度所得税前利润提升至640万美元,全年达2,750万美元,上年同期分别为530万美元和1,850万美元 按照美国通用会计准则(GAAP)计算的摊薄每股收益,本季度为0.60美元,全年为2.09美元,上年同期分别为0.22美元和1.12美元 期末在手订单达1.216亿美元,反映出本季度订单向收入转化的强劲势头 美国德克萨斯州伍德兰兹--(美国商业资讯)-- Perma-...

0评论2026-04-221317